Larotrectinib induces autophagic cell death through AMPK/mTOR signalling in colon cancer

Larotrectinib (Lar) is a highly selective and potent small‐molecule inhibitor used in patients with tropomyosin receptor kinase (TRK) fusion‐positive cancers, including colon cancer. However, the underlying molecular mechanisms specifically in patients with colon cancer have not yet been explored. O...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Wencheng, Zhu, Hangzhang, Zheng, Sixing, Yin, Guang, Yu, Panpan, Shan, Yuqiang, Liu, Xinchun, Ying, Rongchao, Zhu, Hong, Ma, Shenglin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639042/
https://www.ncbi.nlm.nih.gov/pubmed/36251949
http://dx.doi.org/10.1111/jcmm.17530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639042/
https://www.ncbi.nlm.nih.gov/pubmed/36251949
http://dx.doi.org/10.1111/jcmm.17530

Ejemplares similares